Capricor Therapeutics financials
$8.57−1.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $11.1M | $2.3M | $4.0M | $4.9M | $12.1M | $6.2M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $11.1M | $2.3M | $4.0M | $4.9M | $12.1M | $6.2M |
| Gross margin | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$42.9M | -$36.8M | -$29.2M | -$26.3M | -$27.7M | -$25.0M | -$7.7M | -$13.0M | -$11.6M | -$10.3M | -$1.3M | -$6.9M |
| Net income | -$40.7M | -$33.9M | -$30.2M | -$24.6M | -$25.9M | -$24.4M | -$7.1M | -$12.6M | -$11.0M | -$9.8M | -$762.1K | -$6.4M |
| Net margin | — | — | — | — | — | — | −63.9% | −555.2% | −277.0% | −199.6% | −6.3% | −103.3% |
| Diluted EPS | $-0.70 | $-0.59 | $-0.62 | $-0.54 | $-0.57 | $-0.53 | $-0.16 | $-0.38 | $-0.35 | $-0.31 | $-0.02 | $-0.25 |
| EBITDA | -$42.4M | -$36.2M | -$28.7M | -$25.8M | -$27.2M | -$24.6M | -$7.3M | -$12.6M | -$11.2M | -$9.9M | -$973.7K | -$6.6M |
| Operating cash flow | -$31.5M | -$29.3M | -$23.6M | -$19.7M | -$20.1M | -$6.4M | -$14.8M | -$11.6M | -$12.3M | -$1.3M | -$11.6M | -$8.8M |
| Free cash flow | -$37.4M | -$39.1M | -$28.7M | -$23.7M | -$21.4M | -$7.3M | -$15.3M | -$11.7M | -$12.3M | -$1.9M | -$11.6M | -$9.6M |
| Diluted shares | 57.9M | 57.4M | 48.9M | 45.7M | 45.7M | 45.6M | 44.6M | 33.1M | 31.8M | 31.4M | 30.7M | 25.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $20.9M | $105.4M | $287.8M | $19.5M | $23.2M | $28.8M |
| Short-term investments | $217.0M | $173.2M | $30.3M | $79.1M | $99.6M | $116.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $368.7M | $326.3M | $355.9M | $126.4M | $133.6M | $153.8M |
| Total liabilities | $122.5M | $47.6M | $50.2M | $42.6M | $28.6M | $26.1M |
| Shareholders' equity | $246.2M | $278.7M | $305.8M | $83.9M | $105.0M | $127.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology